Efficacy and safety of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) in Chinese patients (Pts) with metastatic adenocarcinoma of the pancreas (MPC): A phase II study

被引：0
|
作者：
Yu, X. [1 ]
Shen, L. [2 ]
Hao, J. [3 ]
Wang, L. [4 ]
Pan, H. [5 ]
Han, G. [6 ]
Xu, J. [7 ]
Zhang, Y. [8 ]
Yang, S. [9 ]
Ying, J. [10 ]
Li, M. [11 ]
Begic, D. [12 ]
Lu, B. [12 ]
Xu, R. [13 ]
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Dept Pancreat & Hepatobiliary Surg, Shanghai 200433, Peoples R China
[2] Peking Univ, Canc Hosp, Beijing Canc Hosp, Oncol, Beijing 100871, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Oncol, Tianjin, Peoples R China
[4] 1st Shanghai Peoples Hosp, Oncol, Shanghai, Peoples R China
[5] Zhejiang Univ, Sir Run Run Shaw Hosp, Oncol, Hangzhou 310003, Zhejiang, Peoples R China
[6] 4th Mil Med Univ, Xijing Hosp, Oncol, Xian, Peoples R China
[7] 307th Hosp PLA AMMS China, Oncol, Beijing, Peoples R China
[8] 1st Hosp Harbin Inst Hematol, Oncol, Harbin, Peoples R China
[9] Henan Prov Anticanc Hosp, Oncol, Zhengzhou, Peoples R China
[10] Zhejiang Canc Hosp, Oncol, Hangzhou, Zhejiang, Peoples R China
[11] Celgene, Biostat, Summit, NJ USA
[12] Celgene, CR&D, Summit, NJ USA
[13] Sun Yat Sen Univ, Affiliated Hosp 1, Oncol, Guangzhou 510275, Guangdong, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
223P
引用
收藏
页码：66 / 67
页数：2
相关论文
共 50 条
  • [41] Expression of SPARC and response to nab-paclitaxel (nab-p) in patients (pts) with metastatic breast cancer (MBC)
    Schneeweiss, Andreas
    Aigner, Julia
    Smetanay, Katherina
    Schuetz, Florian
    Sohn, Christof
    Kriegsmann, Mark
    Jaeger, Dirk
    Zorn, Markus
    Bachinger, Andreas
    Sinn, Hans-Peter
    Marme, Frederik
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] nab-Paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC): Interim efficacy and safety results from the Phase 2 LAPACT Trial
    Philip, P. A.
    Lacy, J.
    Portales, F.
    Sobrero, A.
    Pazo-Cid, R.
    Manzano Mozo, J. L.
    Kim, E. S.
    Dowden, S.
    Zakari, A.
    Borg, C.
    Terrebonne, E.
    Rivera Herrero, F.
    Shiansong Li, J.
    Ong, T. J.
    Nydam, T.
    Hammel, P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [43] Phase IB trial of ADI-PEG 20 (A) plus nab-paclitaxel (nab-P) and gemcitabine (gem) in patients with advanced pancreatic cancer (PC)
    Lowery, Maeve Aine
    Harding, James J.
    Yu, Kenneth H.
    Kelsen, David Paul
    Bomalaski, John S.
    Glassman, Danielle C.
    Covington, Christina M.
    Brenner, Robin
    Hollywood, Ellen
    Barba, Adalberto
    Johnston, Amanda
    Liu, Kay Chia-Wei
    Capanu, Marinela
    Abou-Alfa, Ghassan K.
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [44] APACT: A Phase III Trial of Nab-Paclitaxel (nab-P) Plus Gemcitabine (Gem) Versus Gem Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (PC)
    Tempero, Margaret
    Cardin, Dana
    Biankin, Andrew
    Goldstein, David
    Moore, Malcolm
    O'Reilly, Eileen
    Philip, Philip
    Riess, Hanno
    Macarulla, Teresa
    Yung, Lotus
    Wei, Xinyu
    Lu, Brian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S72 - S72
  • [45] Treatment patterns, clinical characteristics, and outcomes of patients (pts) with metastatic pancreatic cancer (MPC) treated with nab-paclitaxel (nab-P) plus gemcitabine (GEM) in real-life practice: ANICE-Pac trial
    Fernandez, A.
    Salgado, M.
    Garcia, A.
    Buxo, E.
    Vera, R.
    Adeva, J.
    Jimenez, P.
    Quintero, G.
    Llorca, C.
    Canabate, M.
    Lopez, L. J.
    Munoz, A.
    Ramirez, P.
    Gonzalez, P.
    Lopez, C.
    Reboredo, M.
    Gallardo, E.
    Sanchez, M.
    Gallego, J.
    Guillen, C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [46] Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
    Weiss, Glen J.
    Blaydorn, Lisa
    Beck, Julia
    Bornemann-Kolatzki, Kirsten
    Urnovitz, Howard
    Schutz, Ekkhard
    Khemka, Vivek
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (01) : 96 - 102
  • [47] A Phase II study of weekly nab-paclitaxel in combination with gemcitabine in patients with metastatic breast cancer.
    Zhao, Yannan
    Lv, Fangfang
    Chen, Shen
    Lu, Yunhua
    Cao, Enying
    Wang, Zhonghua
    Zhang, Jian
    Zhang, Sheng
    Cao, Jun
    Zheng, Chunlei
    Wang, Leiping
    Wang, Biyun
    Hu, Xichun
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [48] A phase I study of nab-paclitaxel (A), gemcitabine (GEM), and capecitabine (X) in patients with metastatic pancreatic adenocarcinoma (MPA)
    Thach-Giao Truong
    Tempero, Margaret A.
    Kantoff, Emily
    Jones, Kimberly
    Dito, Elizabeth
    Ong, Anna
    Ko, Andrew H.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [49] Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
    Glen J. Weiss
    Lisa Blaydorn
    Julia Beck
    Kirsten Bornemann-Kolatzki
    Howard Urnovitz
    Ekkhard Schütz
    Vivek Khemka
    Investigational New Drugs, 2018, 36 : 96 - 102
  • [50] Phase I study of nivolumab (nivo) plus nab-paclitaxel (nab-P) plus carboplatin (C) in advanced NSCLC: safety and efficacy results
    Waterhouse, David M.
    George, Ben
    Gutierrez, Martin
    Otterson, Greg A.
    Ko, Amy
    Ong, Teng Jin
    Stergiopoulos, Sotirios
    Trunova, Nataliya
    Kelly, Karen
    CANCER RESEARCH, 2016, 76
12345